Grail rises as TD Cowen more than doubles PT on FDA, Medicare optimism
13/10/2026 17:09
BUZZ-Grail rises as TD Cowen more than doubles PT on FDA, Medicare optimism ** Grail GRAL.O shares rise over 2% to $140.53
** TD Cowen hikes PT on cancer test maker to $180 from $88 — implying a 31% upside to last close; keeps 'buy' rating
** Brokerage raises FDA approval chance for GRAL's Galleri early cancer-detection test to 95% from 75% after FDA advisory committee meeting, expects decision in Q127
** Expects favorable Medicare coverage decision in H128
** 5 of 12 brokerages rate GRAL "buy" or above, 7 "hold"; median PT: $120 - data compiled by LSEG
** Including session's moves, stock up ~64% YTD
(Reporting by Miraanta Lowrance in Bengaluru)
Recent news on Grail
See all newsGrail rises as TD Cowen more than doubles PT on FDA, Medicare optimism
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
U.S. RESEARCH ROUNDUP-Chevron, Mobility Global, Tesla
Street View: Grail cancer test's progress boosts prospects for multi-cancer detection market
NASDAQ RESUMED AT 07:05 AM